



COPY OF PAPERS  
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J. Henkin, *et al.*

Serial No.: 09/447,226

Filed: November 22, 1999

For: PEPTIDE ANTIANGIOGENIC  
DRUGS

Case No.: 6356.US.P3

Group Art No.: 1653

Examiner: D. Lukton

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Assistant Commissioner for Patents  
Washington, D.C. 20231, on:

Date of Deposit: March 14, 2002

Tanya Parent

MAR 28 2002

TECH CENTER 1600/2900

Date

**RESPONSE TO RESTRICTION REQUIREMENT AND  
AMENDMENT A**

Director of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

This communication is in response to the Restriction Requirement dated January 14, 2002, having a shortened Statutory Period for Reply of March 14, 2002, pursuant to a one (1) month extension of time under 37 C.F.R. § 1.136(a).

Applicants hereby elect to restrict the invention to the claims of Group I without traverse and elect Example 14, found on page 61, lines 13-23 and recited in Claims 1-14 and 16, as a species for search purposes.

Before examination on the merits, kindly enter this amendment and reconsider the subject application in view of the following remarks.

Text to be deleted is bracketed and bolded to distinguish it from bracketed text which is not meant to be deleted.

Thirty (30) claims, including nineteen (19) independent claims are pending in the subject application.